Question · Q3 2026
Bill Kirk sought clarification on the full-year global medical cannabis revenue guidance of CAD 269 million-CAD 281 million, noting that the year-to-date figure of CAD 211 million implies a significant quarter-over-quarter deceleration in Q4. He asked for the reason behind this expected deceleration. Mr. Kirk also questioned why the Adjusted Gross Margin in the wholesale business (35%) was consistently higher than that of the Canadian consumer cannabis segment.
Answer
Simona King, CFO, confirmed the full-year guidance for global medical cannabis and stated that the company expects a strong Q4, despite the implied deceleration, focusing on the full-year range. She mentioned potential headwinds in some markets but reiterated confidence in achieving the record full-year results. Miguel Martin, Executive Chairman and CEO, explained that the Canadian consumer business has tighter margins due to market dynamics, while wholesale benefits from selling products not readily available globally due to stringent regulatory requirements, contributing to better margins.
Ask follow-up questions
Fintool can predict
ACB's earnings beat/miss a week before the call

